Meghan Rogers
Gerontology · Eatontown, NJNPI 1255883955
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AstraZeneca at 25.8% of the total. 2025 is the largest year on record at $845, 3.1 times the $276 reported in 2021.
Across 122 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$642
- GSK$414
- Actelion Pharmaceuticals US, Inc.$349
- Sanofi$148
- Viatris Specialty LLC$138
- Harmony Biosciences LLC$114
- plus $682 from 13 others
What the payments were for
- Food & beverage$2,34394%
- Education$1446%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $642 |
| GSK | 20 | $414 |
| Actelion Pharmaceuticals US, Inc. | 19 | $349 |
| Sanofi | 8 | $148 |
| Viatris Specialty LLC | 7 | $138 |
| Harmony Biosciences LLC | 7 | $114 |
| Mylan Specialty L.p. | 6 | $99 |
| Boehringer Ingelheim | 6 | $94 |
| Jazz Pharmaceuticals Inc. | 5 | $89 |
| United Therapeutics Corporation | 5 | $86 |
| Insmed, Inc. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Philips North America LLC | 2 | $32 |
| AbbVie | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Baxter Healthcare | 1 | $25 |
| Verona Pharma, Inc. | 1 | $19 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,487 in reported general payments places this provider in the 85th percentile of 374 gerontology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 477 | $448,346 |
| Breo ElliptaFluticasone/Vilanterol | 233 | $133,744 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 76 | $71,351 |
| Spiriva RespimatTiotropium Bromide | 65 | $56,312 |
| Dupixent PenDupilumab | 14 | $50,684 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $37,478 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 51 | $28,331 |
| Incruse ElliptaUmeclidinium Bromide | 58 | $27,374 |
| Spiriva HandihalerTiotropium Bromide | 22 | $22,473 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 119 | $18,928 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $16,265 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 315 | $12,256 |
| Arnuity ElliptaFluticasone Furoate | 27 | $9,806 |
| EliquisApixaban | 11 | $8,838 |
| Wixela InhubFluticasone Propion/Salmeterol | 40 | $8,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $414 | $656,748834 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $642 | $87,616114 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $94 | $84,643116 claims |
| MerckDulera | $17 | $6,93012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 374 gerontology providers in New Jersey.
Other gerontology in Eatontown
- Dana JonesTeaneck$150K
- Jennifer FoxFlemington$76K
- Susan HermidaBrick$33K
- Jihane SaadeNorth Bergen$9K
- Joseph RudolphCamden$8K
- Jennifer LernerNew Brunswick$7K
- Josephine MachadoNew Brunswick$7K
- Remya JamesNew Brunswick$7K
- Anna HaEnglewood$7K
- Myoung ParkBayonne$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.